On September 1, 2020 Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, reported that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma will present at the H.C. Wainwright 22nd Annual Global Investment Conference (Press release, Benitec Biopharma, SEP 1, 2020, https://www.prnewswire.com/news-releases/benitec-biopharma-to-present-at-hc-wainwrights-22nd-annual-global-investment-conference-301121597.html [SID1234564260]). The relevant details are outlined below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Wednesday, September 16, 2020
Event: H.C. Wainwright 22nd Annual Global Investment Conference
Time: 11:30 A.M. EDT
Webcast Link: View Source

Please visit the link above to register for the presentation which will be presented via webcast during the virtual conference. The presentation will also be streamed on the Investor Relations section of the Company’s website, View Source, and a copy of the presentation will be released to Nasdaq and posted on the Company’s website at the above URL prior to the event.

If you would like to arrange a virtual 1×1 meeting with Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec after the presentation, please contact the Benitec IR Team using the details below.